

TABLE 1 Patient demographics and clinical presentation

Patient	Age	Weight	Primary diagnosis	Level of treatment	Time to procedure <sup>1</sup>	Overall Survival <sup>2</sup>
1	15 y	56.3 kg	Alveolar rhabdomyosarcoma (stage 4) initially treated with protocol D9803 for 24 weeks and then auto SCT. Relapsed 15 m later and was treated with irinotecan-temozolomide-palbociclib	T7, T12	16 m 22 d	24 m
2	9 y	30 kg	Wilms tumor initially treated with Reg DD4A 3 drugs (vincristine, dactinomycin, doxorubicin). Had progression and changed to SIOP 4 drugs (VP16, CPM, Carbo, DOX)	L3	70 m 10 d	117 m
	10 y	30.1 kg		L3	76 m	
	11 y	34.7 kg		L3	88 m 2 d	
	13 y	36.6 kg		L3	109 m 13 d	
3	6 y	22.7 kg	Rhabdomyosarcoma of the prostate initially treated with ARST0431 multiagent chemotherapy (vincristine, irinotecan, dactinomycin, IFOS, CPM, VP16, DOXO)	T1, T6, T7, T9	20 m 22 d	24 m
				T11, L2, L3, L4	20 m 29 d	

<sup>1</sup>Time to procedure was measured from the day of diagnosis to the day of the intervention.

<sup>2</sup>Overall survival was measured from the day of diagnosis to the time of death.